Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

MCRB Seres Therapeutics Inc

Price (delayed)

$7.13

Market cap

$62.26M

P/E Ratio

0.81

Dividend/share

N/A

EPS

$8.76

Enterprise value

$84.29M

Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to ...

Highlights
Seres Therapeutics's net income has soared by 188% YoY
The equity has soared by 184% YoY
MCRB's revenue has dropped by 100% year-on-year
Seres Therapeutics's gross profit has shrunk by 100% YoY

Key stats

What are the main financial stats of MCRB
Market
Shares outstanding
8.73M
Market cap
$62.26M
Enterprise value
$84.29M
Valuations
Price to earnings (P/E)
0.81
Price to book (P/B)
1.23
Price to sales (P/S)
N/A
EV/EBIT
1.1
EV/EBITDA
0.93
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$116.59M
Net income
$72.95M
EBIT
$76.4M
EBITDA
$90.27M
Free cash flow
-$86.82M
Per share
EPS
$8.76
EPS diluted
$8.75
Free cash flow per share
-$9.98
Book value per share
$5.79
Revenue per share
$0
TBVPS
$18.86
Balance sheet
Total assets
$164.18M
Total liabilities
$113.72M
Debt
$89.55M
Equity
$50.47M
Working capital
$34.76M
Liquidity
Debt to equity
1.77
Current ratio
2.11
Quick ratio
2.24
Net debt/EBITDA
0.24
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
36.3%
Return on equity
26,673.1%
Return on invested capital
39.1%
Return on capital employed
57.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MCRB stock price

How has the Seres Therapeutics stock price performed over time
Intraday
1.86%
1 week
1.13%
1 month
-25.96%
1 year
-66.68%
YTD
-57.1%
QTD
-49.07%

Financial performance

How have Seres Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$116.59M
Net income
$72.95M
Gross margin
N/A
Net margin
N/A
Seres Therapeutics's net income has soared by 188% YoY
MCRB's revenue has dropped by 100% year-on-year
Seres Therapeutics's gross profit has shrunk by 100% YoY
MCRB's operating income has dropped by 75% year-on-year but it is up by 3.9% since the previous quarter

Price vs fundamentals

How does MCRB's price correlate with its fundamentals

Growth

What is Seres Therapeutics's growth rate over time

Valuation

What is Seres Therapeutics stock price valuation
P/E
0.81
P/B
1.23
P/S
N/A
EV/EBIT
1.1
EV/EBITDA
0.93
EV/Sales
N/A
The EPS has soared by 172% YoY
The equity has soared by 184% YoY
MCRB's revenue has dropped by 100% year-on-year

Efficiency

How efficient is Seres Therapeutics business performance

Dividends

What is MCRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MCRB.

Financial health

How did Seres Therapeutics financials performed over time
The total assets is 44% higher than the total liabilities
MCRB's current ratio has soared by 124% QoQ and by 26% YoY
The quick ratio has soared by 122% QoQ and by 74% YoY
MCRB's debt is 77% greater than its equity
The equity has soared by 184% YoY
Seres Therapeutics's debt to equity has surged by 149% YoY but it has shrunk by 73% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.